Halia Therapeutics Completes Enrollment in Phase 2a Clinical Trial of HT-6184 for Myelodysplastic Syndrome (MDS)
LEHI, Utah, June 4, 2025 /PRNewswire/ -- Halia Therapeutics, a clinical-stage biopharmaceutical…
Cango Inc. Completes PRC Business Sale, Strengthens Board to Drive Global Bitcoin Focus
SHANGHAI, May 29, 2025 /PRNewswire/ -- Cango Inc. (NYSE: CANG) ("Cango" or the…
